Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Dacoplice 15mg Tablet
Dacoplice 15mg Tablet contains Dacomitinib, an antineoplastic agent classified as a tyrosine kinase inhibitor. It is prescribed as a first-line treatment for adults diagnosed with non-small cell lung cancer that has metastasized and exhibits specific genetic mutations.
Uses of Dacoplice 15mg Tablet
Dacoplice 15mg Tablet is indicated for the initial treatment of non-small cell lung cancer in adults, particularly when the cancer shows specific genetic alterations.
Benefits of Dacoplice 15mg Tablet
This medication offers the benefit of potentially inhibiting the growth and spread of cancer cells in patients with non-small cell lung cancer, thus improving overall survival and quality of life.
Mechanism of Action of Dacoplice 15mg Tablet
Dacoplice 15mg Tablet works by targeting and blocking the activity of certain enzymes known as tyrosine kinases, which are involved in the growth and spread of cancer cells. By inhibiting these enzymes, the medication helps to slow down or halt the progression of the disease.